Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Schistosomiasis - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 36 | Code: MRS - 18553


Global Markets Directs, Schistosomiasis Pipeline Review, H2 2014, provides an overview of the Schistosomiasiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Schistosomiasis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Schistosomiasis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Schistosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Schistosomiasis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Schistosomiasis Overview 6
Therapeutics Development 7
Pipeline Products for Schistosomiasis - Overview 7
Pipeline Products for Schistosomiasis - Comparative Analysis 8
Schistosomiasis - Therapeutics under Development by Companies 9
Schistosomiasis - Therapeutics under Investigation by Universities/Institutes 10
Schistosomiasis - Pipeline Products Glance 11
Early Stage Products 11
Schistosomiasis - Products under Development by Companies 12
Schistosomiasis - Products under Investigation by Universities/Institutes 13
Schistosomiasis - Companies Involved in Therapeutics Development 14
BioDiem Ltd 14
Concert Pharmaceuticals, Inc. 15
Kancera AB 16
LondonPharma Ltd 17
Schistosomiasis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
BDM-I - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
D-Praziquantel - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
intestinal schistosomiasis vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule for Schistosomiasis - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Schistosomiasis - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Schistosomiasis - Recent Pipeline Updates 29
Schistosomiasis - Dormant Projects 31
Schistosomiasis - Product Development Milestones 32
Featured News & Press Releases 32
Aug 23, 2013: BioDiem US patent for skin and wound infections 32
Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites 32
Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I 33
Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I 33
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 34

Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables

Number of Products under Development for Schistosomiasis, H2 2014 7
Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Schistosomiasis - Pipeline by BioDiem Ltd, H2 2014 14
Schistosomiasis - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 15
Schistosomiasis - Pipeline by Kancera AB, H2 2014 16
Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 21
Number of Products by Stage and Molecule Type, H2 2014 23
Schistosomiasis Therapeutics - Recent Pipeline Updates, H2 2014 29
Schistosomiasis - Dormant Projects, H2 2014 31

List of Figures

Number of Products under Development for Schistosomiasis, H2 2014 7
Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Top 10 Molecule Types, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 22

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing